Touchlight awarded grant extension to further develop DNA-enabled Biobatteries with U.S. Office for Naval Research and UK Defence Science & Technology Laboratory Published: 26 April 2024 Touchlight, a biotechnology CDMO…
Read More
University of Liverpool to use Touchlight’s rapid enzymatic dbDNA in fully personalised neoantigen cancer vaccine clinical study Published: 4 April 2024 The UK’s Medical Research Council is funding a 10-patient…
Read More
Touchlight awarded tender to supply enzymatic dbDNA to CPI’s RNA Centre of Excellence Published: 28 March 2024 Touchlight, an innovation-driven CDMO enabling the development of genetic medicines with its doggybone…
Read More
Elena Stoyanova, Hyatt Balke-Want, Marianna Romito, Debra Barberini In this virtual seminar, cell engineering scientists from Stanford University, Touchlight Genetics, and MaxCyte share promising advances in non-viral gene therapy. Join…
Read More
Touchlight’s enzymatic doggybone DNA used in the manufacture of Versameb’s VMB-100 for first-in-human clinical study Published: 21 November 2023 Based on prior manufacturing agreement that encompasses usage of Touchlight’s doggybone…
Read More
Download the poster here
Read More
Curia expands biologics capabilities with access to Touchlight’s doggybone DNA Published: 24 July 2023 Curia collaborates with Touchlight to expand its mRNA manufacturing offering to enable access to enzymatic doggybone…
Read More
20Med Therapeutics and Touchlight to collaborate on novel vaccine delivery platform project Published: 18 April 2023 Curia collaborates with Touchlight to expand its mRNA manufacturing offering to enable access to…
Read More
Touchlight secures government grant to support its £14m investment in scale-up DNA manufacturing Published: 29 March 2023 headline Hampton, UK, 29 March 2023 – Touchlight, a CDMO pioneering enzymatic DNA production…
Read More
Touchlight announces first FDA clearance of an IND utilising doggybone DNA Published: 28 February 2023 Enzymatic doggybone DNA material used in GMP production of a cell therapy by a US-based…
Read More
